Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe

Ruff, L.; Bagshaw, Emma; Aracil, Javier; Velard, Marie-Eve; Pardhanani, Gianni; Hepp, Zsolt

doi:10.1080/13696998.2016.1199430

Cited by 6 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also associated with a substantial economic burden in terms of direct cost for the healthcare system, estimated to range from €269 to €702 per patient per year. Ruff et al 24 reported that use of Onab-A resulted in estimated cost savings of €97.200 for 100,000 patients for the Italian health system. The clinical efficacy of Onab-A injections has been widely demonstrated in large, randomised clinical trials for both neurogenic and idiopathic patients with UUI.…”

Section: Discussionmentioning

confidence: 99%

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

et al. 2018

View full text Add to dashboard Cite

Objective: Onabotulinumtoxin-A has been approved for wet overactive bladder refractory to anticholinergics in randomised controlled trials; however, data from real-life practice are scarce. This study was designed to assess the efficacy of intravesical onabotulinumtoxin-A injections, focusing on health status, urinary symptoms and subjective satisfaction. Methods: Data from consecutive patients with overactive bladder-refractory to anticholinergics treated with onabotulinumtoxin-A were prospectively collected and analysed. Standard doses (100-150 U) were used, followed by repeat sessions when clinical benefits diminished. Efficacy and safety of repeat onabotulinumtoxin-A administrations were assessed at 12-week post-injection. Clinical parameters evaluated were: change in the magnitude and frequency of incontinence, urgency and nocturia episodes, change in the number of pads used and procedural complications. Quality of life was evaluated using the 36-Item Short-Form Health Survey, Overactive Bladder Screener and Treatment Benefit Scale questionnaires. Results: Consecutive overactive bladder-refractory to anticholinergics patients (n = 22) (median duration of oral therapy: 10 months) were enrolled. No intraoperative complications occurred, but two urinary retention cases were recorded. Forty-five percent of patients (10/22) were retreated (median duration of perceived benefits: 18 months, range: 8-55 months). The number of urinary incontinence, frequency and nocturia episodes, and pads used went from 3.6, 11.3, 2.7 and 2.4 preoperatively to 1.0, 5.8, 0.7 and 0.7 postoperatively (p < 0.005). Quality of life (36-Item Short-Form Health Survey) was significantly improved and symptom scores (Overactive Bladder Screener) were reduced, from 34.5 to 17.1 at week 12 (p < 0.05). Eighty-seven percent of patients indicated improvement/great improvement in their condition (Treatment Benefit Scale). Conclusion: Intradetrusor injections of onabotulinumtoxin-A in patients with overactive bladder-refractory to anticholinergics significantly improved health status and urinary symptoms, with high subjective satisfaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In 2006, a study from the UK demonstrated that BoNT-A injections for overactive bladder irrespective of the pathology were more cost-effective over a 1-year duration than standard care with regular office follow-ups and anticholinergic medication or clean self-intermittent catheterization. This effectiveness was reproduced by other studies from the USA, Europe, and the UK for a 5-year cost-effective and sensitivity analysis comparing BoNT-A injections to conservative management and surgical intervention [6][7][8][9]. All of this economic evidence, coupled with numerous trials demonstrating the effectiveness of botulinum injections for treatment of overactive bladder symptoms and other emerging uses, has popularized its application among urologists and has led to its inclusion as second-and third-line management modality in numerous urology care guidelines reviewed and published by authorities such as the European Association of Urology (EAU), American Urological Association (AUA), and International Continence Society (ICS).…”

Section: Introductionmentioning

confidence: 88%

Urological Applications of Botulinum Toxin A

Yaiesh¹,

Almutairi²,

Al‐Terki³

et al. 2018

Botulinum Toxin

View full text Add to dashboard Cite

Botulinum toxin A (BoNT-A) has seen in the last two decades an increased level of application in urological practice, first FDA approved in 2011 for neurogenic detrusor overactivity and then later in 2013 for refractory overactive bladder. Hundreds of studies have been published in literature assessing the chemical structure of botulinum toxins and how urothelial injections in the lower urinary tract and vesical instillations can be employed in the management of a spectrum of urological conditions particularly voiding dysfunction. The consensus is still out on toxin A preparations, mode and pattern of application whether instilled or injected intradetrusally, units used, as well as time to onset and duration of effect of injections and is still a dense research topic. This is reflected in the continuously changing and differing grades of recommendations between societies of urological practitioners such as the EAU and AUA, among others. This chapter discusses both the FDA-approved and experimental applications of botulinum toxin A in urology, indications, techniques, and points of debate.

show abstract

Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder

Tay

Harry

Malde

et al. 2021

Urology

View full text Add to dashboard Cite

Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe

Cited by 6 publications

References 24 publications

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

Urological Applications of Botulinum Toxin A

Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder

Contact Info

Product

Resources

About